VB-111 in Surgically Accessible Recurrent/Progressive GBM
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California, Los Angeles (ucla)
Los Angeles, California, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Ut Health San Antonio Md Anderson Cancer Center (mays Cancer Center)
San Antonio, Texas, United States
- Huntsman Cancer Institute (hci), University of Utah
Salt Lake City, Utah, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 1 Aug 2020
- Primary completion
- 1 Aug 2024
- Completion
- 1 Aug 2024
- Last update posted
- 10 Jun 2025
- Registered enrollment
- 15
- Registry id
- NCT04406272
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.